CSPC Pharmaceutical Group Limited

CSPCY | OTC

Price Alert Chart Builder DCF Calculator

$4.07

+$0.13 (+3.30%)

Nov 2, 2026, 11:13 AM ET · Market open

Overview Rating Statistics Financials Earnings Ownership Dividends Profile

+3.30%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Nov 2, 2026

67.4

+3.6 pts

Fundamentals Strong

Market Sentiment Neutral

Moat Narrow

Sector Rank #77/1028 (Top 7%)

Full Analysis

Key Statistics

Market Data

Market Cap $11.87B

1D Range

4.07 4.07

52W Range

3.31 5.45

Valuation (TTM)

PE 42.38

PB 2.09

EV/EBITDA 6.09

Valuation (NTM)

Forward PE N/A

Forward PEG 0.13

Price Target $0.00

Cash Flow

FCF Yield 15.8%

SBC Adj. FCF Yield 15.7%

SBC Impact -0.9%

Margins

Gross Margin 71.9%

Operating Margin 27.9%

FCF Margin 39.6%

Growth (CAGR)

Revenue 3Y | 5Y 11.8% | 29.9%

Dil EPS 3Y | 5Y 26.6% | 42.7%

FCF 3Y | 5Y 63.3% | 43.8%

Returns

ROA 13.1%

ROE 20.7%

ROIC 17.4%

Financial Health

Net Cash

¥17.95B ($2.65B)

Current Ratio 2.14

Interest Coverage 289.44

Dividends

Div Yield 4.31%

Payout Ratio 25.9%

FCF Payout Ratio 20.1%

All Key Statistics

Loading financial charts...

Profile

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and inte...

Sector Healthcare

Industry Drug Manufacturers - General

Employees 19,700

IPO Date Mar 25, 2021

Website www.cspc.com.hk

Fiscal Year n/a

Full Company Profile

Latest News

4 months ago · reuters.com

AstraZeneca signs CSPC China deal for experimental kidney disease drugs

AstraZeneca has entered into a deal worth up to $1.77 billion with CSPC ‌Pharmaceutical Group to discover and develop experimental medicines with the potential to treat kidney diseases, the Chinese drugmaker said on Thursday.